Q1 2024 Earnings Summary
- Amgen is rapidly advancing MariTide, a promising obesity treatment, and plans to move swiftly to Phase III studies due to positive Phase II results and recognizing a huge unmet need in the marketplace. ,
- Amgen's deep expertise in CD19-directed therapeutics, inflammation, and autoimmunity positions it to capitalize on new opportunities, inspired by recent developments in systemic sclerosis and refractory rheumatoid arthritis treatments.
- Amgen is leveraging its experience in developing CD3 bispecifics to advance solid tumor targeting T-cell engaging therapies, expecting future progress on medicines like AMG 651 and tarlatimab.
- Executives were unable to provide specific timelines or details on the initiation of Phase III studies for MariTide, their obesity candidate, indicating potential uncertainties in the development timeline.
- Lack of updates on AMG 651, their EGFR-CD3 bispecific program, with executives stating they have no news to share, possibly signaling slow progress or challenges in the development.
- When questioned about safety metrics for MariTide, executives avoided providing detailed information, which may raise concerns about safety issues in the ongoing study.
-
MariTide Differentiation
Q: What differentiates MariTide from competitors?
A: Management highlighted MariTide's broad and differentiated profile , with potential advantages in efficacy, tolerability, and dosing interval. They are confident in its ability to address unmet medical needs and provide access for millions of patients , positioning it as a competitive product in the market. -
Manufacturing Capacity for MariTide
Q: Can you meet manufacturing demands for MariTide?
A: The company is confident in supplying millions of patients with MariTide , leveraging their experience in biotherapeutic manufacturing. They emphasized their commitment to supplying every patient, every time , noting that monthly or less frequent dosing reduces the need for injection devices compared to weekly therapies. -
Tarlatamab Launch Preparation
Q: How are you preparing for Tarlatamab's launch?
A: Amgen is well-prepared for Tarlatamab's potential approval , with trained field personnel and plans for broad access upon approval. They view it as a major advance in small cell lung cancer treatment and have initiated three Phase III studies to move it into earlier therapy lines. -
MariTide Expansion Plans
Q: Will MariTide target conditions beyond obesity and diabetes?
A: Management is planning a broad Phase III program to address unmet needs in obesity and related conditions , continuing to develop MariTide as intended. -
TEZSPIRE in COPD
Q: What's TEZSPIRE's potential role in COPD?
A: TEZSPIRE showed clinically meaningful activity in a Phase II COPD trial , with full data to be presented at the American Thoracic Society Meeting. The company recognizes COPD's heterogeneity and is interested in further development due to the drug's mechanism targeting type 2 inflammation. -
Rocatinlimab Differentiation
Q: How will Rocatinlimab compete in atopic dermatitis?
A: Rocatinlimab aims for a competitive profile with strong efficacy and excellent patient experience. The Phase III HORIZON study involves 726 patients , and management believes it can be effectively positioned against treatments like Dupixent. -
MariTide Phase III Timing
Q: When will MariTide's Phase III start, and how will you accelerate it?
A: The company plans to complete Phase II and work swiftly with regulators on the Phase III program , moving as rapidly as possible to address the huge unmet need. -
BLINCYTO in Autoimmune Disorders
Q: Any plans for BLINCYTO in autoimmune diseases?
A: Management is well-organized to explore BLINCYTO's potential in autoimmune disorders , finding recent findings inspiring and planning to report more in the future. -
AMG 651 Oncology Development
Q: Any updates on AMG 651's development in oncology?
A: The company continues to study AMG 651 and other solid tumor targeting bispecific T-cell engagers , with no new data yet but confidence inspired by tarlatamab's progress.
Research analysts covering AMGEN.